000272587 001__ 272587
000272587 005__ 20241018164447.0
000272587 0247_ $$2doi$$a10.2147/NDT.S474584
000272587 0247_ $$2pmid$$apmid:39372876
000272587 0247_ $$2pmc$$apmc:PMC11453152
000272587 0247_ $$2ISSN$$a1176-6328
000272587 0247_ $$2ISSN$$a1178-2021
000272587 037__ $$aDZNE-2024-01208
000272587 041__ $$aEnglish
000272587 082__ $$a610
000272587 1001_ $$aVeith Sanches, Linda$$b0
000272587 245__ $$aSEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study.
000272587 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2024
000272587 3367_ $$2DRIVER$$aarticle
000272587 3367_ $$2DataCite$$aOutput Types/Journal article
000272587 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729176235_2183
000272587 3367_ $$2BibTeX$$aARTICLE
000272587 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272587 3367_ $$00$$2EndNote$$aJournal Article
000272587 520__ $$aNeuropsychiatric symptoms in particular impair health-related quality of life (QoL) of patients with Parkinson's disease and atypical Parkinsonian syndromes. For this reason, various scales have been developed for detection of neuropsychiatric symptoms, such as the Scale for evaluation of neuropsychiatric disorders in Parkinson's disease (SEND-PD).First, the objective of this study was to explore the interrelation between the SEND-PD and clinical parameters in patients with Parkinson's disease and thus confirm its validity. In addition, the applicability in a well-defined cohort of patients with atypical Parkinsonian syndromes was investigated for the very first time.A clinically well-defined cohort of 122 patients with Parkinson's disease (PD), 55 patients with Progressive Supranuclear Palsy (PSP) and 33 patients with Multiple System Atrophy (MSA) were analyzed. First, the SEND-PD was correlated with established disease-specific scores in patients with PD. Next, the results of the SEND-PD were compared between the different Parkinsonian syndromes.The SEND-PD showed a strong significant correlation with several scores, especially the UPDRS I (Rho = 0.655) and GDS-15 (Rho = 0.645). Depressive burden was significantly higher in MSA patients in comparison to the PD patient cohort (PD, 3.8 ± 3.3; MSA, 5.45 ± 3.87), while PSP patients showed significantly less psychotic (PD 1.6 ± 2.1; PSP 0.6 ± 0.9) and impulse control disorders (PD 0.3 ± 1.0; PSP 0.02 ± 0.1).The SEND-PD is a useful, brief and highly applicable screening tool for neuropsychiatric symptoms in PD, but not in atypical Parkinsonism, as their unique neuropsychiatric symptom composition is not fully captured.
000272587 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272587 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272587 650_7 $$2Other$$aParkinsonian syndromes
000272587 650_7 $$2Other$$aSEND-PD
000272587 650_7 $$2Other$$aneuropsychiatric symptoms
000272587 7001_ $$00000-0003-0638-8571$$aGreten, Stephan$$b1
000272587 7001_ $$aDoll-Lee, Johanna$$b2
000272587 7001_ $$aRogozinski, Sophia Marie$$b3
000272587 7001_ $$aHeine, Johanne$$b4
000272587 7001_ $$aKrey, Lea$$b5
000272587 7001_ $$aUlaganathan, Sarana$$b6
000272587 7001_ $$0P:(DE-2719)9003066$$aJensen, Ida Marie Louise$$b7$$udzne
000272587 7001_ $$0P:(DE-2719)2813308$$aHöllerhage, Matthias$$b8
000272587 7001_ $$aSani, Sam Sadeghi$$b9
000272587 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b10$$udzne
000272587 7001_ $$aWegner, Florian$$b11
000272587 7001_ $$aKlietz, Martin$$b12
000272587 773__ $$0PERI:(DE-600)2180554-4$$a10.2147/NDT.S474584$$gVol. 20, p. 1849 - 1859$$p1849 - 1859$$tNeuropsychiatric disease and treatment$$v20$$x1176-6328$$y2024
000272587 8564_ $$uhttps://pub.dzne.de/record/272587/files/DZNE-2024-01208.pdf$$yOpenAccess
000272587 8564_ $$uhttps://pub.dzne.de/record/272587/files/DZNE-2024-01208.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272587 909CO $$ooai:pub.dzne.de:272587$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000272587 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003066$$aExternal Institute$$b7$$kExtern
000272587 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000272587 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272587 9141_ $$y2024
000272587 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROPSYCH DIS TREAT : 2022$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-30T20:09:59Z
000272587 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-30T20:09:59Z
000272587 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000272587 915__ $$0LIC:(DE-HGF)CCBYNC3$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 3.0
000272587 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272587 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000272587 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000272587 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000272587 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x1
000272587 980__ $$ajournal
000272587 980__ $$aVDB
000272587 980__ $$aUNRESTRICTED
000272587 980__ $$aI:(DE-2719)1111015
000272587 980__ $$aI:(DE-2719)1110002
000272587 9801_ $$aFullTexts